Australian Journal of General Practice
MBBS (Melb), DCH (London), FRANZCOG, CGO, Consultant Gynaecological Oncologist, The Women’s Hospital, Frances Perry House, Vic
Molecular targeting agents are revolutionising treatment options, particularly poly adenosine diphosphate–ribose polymerase inhibitors, especially for patients with an underlying BRCA mutation.